Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25496037 | 1.00 | AHCY (0.43) | AHCYPRMT6P2RY12P2RY2P2RY1 | |
| SCHEMBL26533861 | 0.92 | PRMT6 (0.40) | AHCYPRMT6P2RY12BMPR1B | |
| SCHEMBL25495950 | 0.87 | PRMT5 (0.38) | — | |
| SCHEMBL25496131 | 0.87 | PRMT5 (0.38) | — | |
| SCHEMBL26533859 | 0.87 | PRMT6 (0.40) | PRMT6P2RY12ADORA1 | |
| SCHEMBL20337209 | 0.86 | TYMP (0.43) | P2RY12P2RY2P2RY1P2RY6ADORA1 | |
| SCHEMBL20353032 | 0.86 | TYMP (0.43) | P2RY12P2RY2P2RY1P2RY6ADORA1 | |
| SCHEMBL26327164 | 0.86 | AHCY (0.59) | AHCY | |
| SCHEMBL25496027 | 0.86 | AHCY (0.59) | AHCY | |
| SCHEMBL20337202 | 0.84 | PRMT6 (0.39) | PRMT6P2RY12ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | AHCY 1261/4885PRMT6 1569/4885P2RY12 434/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | AHCY 4633/4885PRMT6 1677/4885P2RY12 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.